Hutchmed (China) Limited Publication of Form 20-F

TIDMHCM

Hutchmed (China) Limited

28 February 2023

Press Release

Publication of Form 20-F

Hong Kong, Shanghai & Florham Park, NJ: Tuesday, February 28, 2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today published the Form 20-F for the financial year ended December 31, 2022. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/3620R_1-2023-2-28.pdf and also on the website of the Company at www.hutch-med.com.

About HUTCHMED

HUTCHMED (Nasdaq/A M:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. t is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. t has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn .

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President                   +852 2121 8200 
Annie Cheng, Vice President                       +1 (973) 306 4490 
 
Media Enquiries 
Americas - Brad Miles, Solebury Trout             +1 (917) 570 7340 (Mobile) 
                                                   bmiles@soleburystrat.com 
Europe - Ben Atwell / Alex Shaw, FTI Consulting   +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 
                                                  (Mobile) 
                                                  HUTCHMED@fticonsulting.com 
Asia - Zhou Yi, Brunswick                         +852 9783 6894 (Mobile) 
                                                   HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
Atholl Tweedie / Freddy Crossley, 
 Panmure Gordon (UK) Limited                      +44 (20) 7886 2500

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRANKFBPDBKDQBB

(END) Dow Jones Newswires

February 28, 2023 07:15 ET (12:15 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024